INVESTING IN THE AGE OF LONGEVITY

13 November 2019, Science Gallery, London

CONNECT, COLLABORATE, INVEST

The science of ageing is progressing rapidly and with it comes a new industry, with hundreds of early stage companies now in existence and the first publicly listed companies beginning to appear.

Master Investor’s one day masterclass, Investing in the Age of Longevity, aims to bring together investors, advisors, academia and businesses working in the field of Longevity to provide an independent and powerful platform to showcase the latest innovations in this field with a view to fostering collaboration and exploring investment opportunities.

WHY ATTEND?

Network with investors and experts in the field of longevity.

Be the first to learn about opportunities to invest in this space.

Strengthen your IR activities by connecting with retail investors.
Generate new leads for fundraising and/or selling your products or services.
SPEAKERS

Dr. Aubrey de Grey

Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. 

He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage.

Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

Nir Barzilai MD

Dr. Barzilai is a chaired Professor of Medicine and Genetics and Director of the biggest Center in the world to study the Biology of Aging. He is the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award. He is leading the TAME (Targeting/Taming Aging with Metformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions. He is a founder of CohBar Inc. (now public company) and Medical Advisor for Life Biosciences. He is on the board of AFAR and CohBar He has been featured in major papers, TV program and documentaries (TEDx and TEDMED) and has been consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, several International Banks, The Vatican, Pepsico, Milkin Institute, The Economist and Wired Magazine.

Laura Demming

Laura is the founder and managing director of the Longevity Fund, an early stage venture capital fund focused on extending healthy human lifespan. After years working on nematode longevity at the UCSF graduate school, Laura matriculated at MIT at 14 and 2 years later participated in the inaugural Thiel Fellowship class. Since then, she has built Longevity Fund and AGE1, funds focused on helping start and fund longevity companies.

About Longevity Fund:
Longevity Fund is an early stage venture capital fund investing in breakthrough longevity companies taking on age-related disease. Since closing the first fund in 2013, Longevity Fund companies have collected >$500M in follow-on funding, resulting in the 2018 IPO of the first company dedicated to reversing the diseases of aging, and multiple programs in clinic to reverse or prevent age-related disease.

Reason

Reason is co-founder and CEO of Repair Biotechnologies, a biotech startup working on means of rejuvenation of the thymus and reversal of atherosclerosis. He is the founder and writer of Fight Aging!, which has been a leading voice in the longevity biotechnology and patient advocacy communities for more than fifteen years. Reason is also an active angel investor in the rejuvenation biotechnology space, and has for many years led and aided non-profit fundraising for academic research into rejuvenation via repair of molecular damage.

About Repair Biotechnologies:
Repair Biotechnologies, Inc. is a biotechnology company with the mission to develop and bring to the clinic therapies that significantly improve human healthspan through targeting the causes of age-related diseases and aging itself. Founded in 2018, Repair Biotechnologies is developing therapies with the goals of regenerating the thymus, treating cancer, and reversing atherosclerosis.

Liz Parrish

Elizabeth Parrish, the Founder and CEO of BioViva, is a humanitarian, entrepreneur, innovator, author, podcaster, and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of regenerative medicine modalities, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach. Dedicated to the cause of improving and safeguarding more and more lives, Elizabeth asserts, “We are focused on saving as many lives as possible by making tomorrow’s therapies available. This is about Life and Death. Risk aversion and the delaying the approval of therapies that have been successful in research simply kills.”

About BioViva:
BioViva, a trail-blazing medical data analysis and research and development company, was started to change the face of healthcare treatments by bringing enhanced and definitive solutions for some of the most perilous diseases. The inspiration came from a life-changing incident when the founder’s son was diagnosed with Type 1 Diabetes. On the path to find the most adequate treatment for him, she was confronted with the reality of children suffering from genetic diseases. She also discovered that, although laboratory animals have been successfully treated for many of these diseases, those therapies haven’t yet been made available to humans, because of the medical profession’s exaggerated risk aversion and the FDA’s precautionary attitude. This meant that despite the discovery of appropriate therapies, the kids die because these therapies have not yet been through a lengthy and extremely expensive chain of paperwork and clinical trials. Determined to change this condition, she established BioViva. Today, BioViva analyzes biomarkers from trials and studies involving patients referred to the clinics by its partner company, Integrated Health Systems. The company is focused on speeding up the number of medical innovations by cooperating with companies that offer consenting patients pioneering therapies that they cannot get in the United States. Using medical researchers to oversee the patients, it beats the gold standard of the US FDA and creates exponential technology for the future. BioViva is the first company in the world to look at the data of regenerative gene therapies in humans.

Declan Doogan

Details coming soon.

VENUE AND TICKET INFORMATION

VENUE

Science Gallery London
Great Maze Pond
London SE1 9GU

TICKETS

Standard ticket: 300 GBP

Tickets are strictly limited and available on a first-come, first-served basis.

This event is CPD registered, allowing you to add it to your CV.

SEND US A MESSAGE

Get in touch today for a no obligation consultation from our Head of Business Development, Amanda Taylor. You can also reach Amanda on +44 (0) 20 7164 6414.